Despite advances in neoadjuvant therapy for patients with HER2-positive early breast cancer (EBC), critical challenges persist that include treatment-related toxicity. A meaningful subset of patients do not achieve pathological complete response, a key predictor of long-term outcomes. Antibody-drug conjugates (ADCs) have emerged as a potentially transformative class in this space. Already reshaping outcomes in advanced disease, ADCs are now generating momentum in both adjuvant and neoadjuvant settings for patients with HER2-positive EBC. To help facilitate this shift, this activity utilizes a series of Time-Outs, a case-based, microlearning-inspired approach in which leading experts navigate challenging clinical scenarios, pausing at key clinical inflection points to discuss critical nuances and optimal decision-making for patients with HER2-positve EBC. Through this strategy faculty address a variety of important clinical considerations related to integrating ADCs into routine practice for this subset of patients.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 201 King of Prussia Rd.
Pricing
CME included with membership
| Integrative Psychiatry Certificate Program | $3,350 |
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Addiction Psychiatry
- Adolescent Medicine
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Internal Medicine
- General Operative Anesthesia
- General Otolaryngology
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Hospice & Palliative Medicine
- Medical Oncology
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Pain Medicine
- Physical Medicine & Rehabilitation
- Practice Management & Ethics
- Primary Care Sports Medicine
- Pulmonary Disease
- Radiation Oncology
- Regional Anesthesia & Acute Pain
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Thoracic Surgery
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Rehabilitation
- Sports & Exercise Medicine
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- includes Case-based learning
- includes Microlearning
- Credit · Up to 0.75 credits
- Commercial Support
-
ReleasedSep 3, 2026
-
Last day to claim creditMar 4, 2027 5 months left
-
PRIME Education, Inc. (PRIME®) Risk Stratification and Tailoring Treatment in HER2+ Early Breast Cancer
-
Physicians’ Education Resource The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing
-
Learner’s Digest International (TM) Antibody Drug Conjugates in Advanced HR+/HER2 Breast Cancer and Triple-Negative Breast Cancer
-
EfficientCME, CME Outfitters, LLC From Data to Decisions: An Integrated CME Activity Designed to Assess and Compare the Practice Patterns of Specialists and General Oncologists Related to the Management of HER2-Negative Metastatic Breast Cancer
-
EfficientCME, CME Outfitters, LLC Unveiling HER2-Low and Ultralow Expression in mBC: Implications for the Multidisciplinary Care Team
-
Efficient CME, CME Outfitters, LLC Reshaping the Paradigm in Hormone Receptor Positive, HER2-negative Early Breast Cancer: How Next Generation SERDs May Challenge the Adjuvant Treatment Landscape
